CD19 and acute lymphoblastic leukemia: For example, although 70–90% of relapsed and/or refractory ALL patients show durable responses to CD19 targeted CAR-T cell therapy, recent follow-up data suggest development of a common disease resistance mechanism, including downregulation/loss of CD19 antigen in 30–70% of patients who have recurrent disease after treatment42,43.